Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
0.37 EUR | -4.02% | -5.13% | -19.57% |
05-07 | GenSight Biologics S.A. announced that it expects to receive ?1.546199 million in funding | CI |
04-05 | GenSight: financial visibility assured until the end of April | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-19.57% | 42.57M | |
+9.83% | 115B | |
+10.80% | 105B | |
-10.84% | 22.71B | |
-1.40% | 21.83B | |
-10.63% | 18.18B | |
-41.92% | 16.52B | |
-15.11% | 16.01B | |
+6.62% | 14.14B | |
+17.53% | 10.71B |
- Stock Market
- Equities
- SIGHT Stock
- News GenSight Biologics S.A.
- Gensight Biologics Pulls Marketing Authorization Application in Europe for Lumevoq Gene Therapy